Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $52.56

Shares of Keros Therapeutics, Inc. (NASDAQ:KROSGet Free Report) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $52.56.

Several research firms have recently commented on KROS. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. HC Wainwright decreased their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. Cantor Fitzgerald downgraded Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Finally, William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th.

Get Our Latest Stock Analysis on Keros Therapeutics

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $10.49 on Thursday. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The business has a 50 day simple moving average of $22.31 and a 200 day simple moving average of $43.44. The firm has a market capitalization of $424.95 million, a P/E ratio of -2.01 and a beta of 1.39.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC increased its holdings in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Holocene Advisors LP boosted its stake in shares of Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after acquiring an additional 154,784 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after acquiring an additional 46,041 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

(Get Free Report

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

See Also

Analyst Recommendations for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.